C12N 2330/50
Biochemical production, i.e. in a transformed host cell
C12N2330/50 (Biochemical production, i.e. in a transformed host cell) appears on 540 US grants and 1,034 published applications in this corpus.
Search patents in C12N- Granted patents
- 540
- Published applications
- 1,034
- Assignees
- 487
- Inventors
- 1,914
- Latest grant
- 11 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2002 | 1 | 0 |
| 2003 | 0 | 3 |
| 2004 | 0 | 4 |
| 2005 | 0 | 2 |
| 2006 | 0 | 4 |
| 2007 | 0 | 0 |
| 2008 | 0 | 6 |
| 2009 | 2 | 9 |
| 2010 | 2 | 17 |
| 2011 | 4 | 17 |
| 2012 | 6 | 33 |
| 2013 | 12 | 31 |
| 2014 | 21 | 43 |
| 2015 | 19 | 43 |
| 2016 | 28 | 61 |
| 2017 | 30 | 61 |
| 2018 | 41 | 88 |
| 2019 | 54 | 103 |
| 2020 | 39 | 80 |
| 2021 | 58 | 78 |
| 2022 | 51 | 91 |
| 2023 | 39 | 84 |
| 2024 | 43 | 78 |
| 2025 | 50 | 59 |
| 2026 | 40 | 39 |
By publication year. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Vectors and compositions for treating hemoglobinopathies11 Aug 2026US 12,703,864 B2Children's Medical Center Corporation
- Viral vectors for treating Parkinson's disease4 Aug 2026US 12,697,360 B2American Gene Technologies International Inc.
- RAAV-based compositions and methods for treating amyotrophic lateral sclerosis23 Jun 2026US 12,662,669 B2University of Massachusetts
- Isolated recombinant oncolytic adenoviruses, pharmaceutical compositions, and uses thereof for drugs for treatment of tumors and/or cancers16 Jun 2026US 12,653,851 B2Hangzhou Converd Co., Ltd.
- Targeting peptides for directing adeno-associated viruses (AAVs)16 Jun 2026US 12,653,904 B2California Institute of Technology
- Novel internal ribosome entry site (ires) and intron sequences1 Oct 2026US 2026/0297579 A1Ginkgo Bioworks, Inc.
- Analytical device for real time luminescence during temperature hold and ramp as used in real time cellular thermal shift assay1 Oct 2026US 2026/0297593 A1The United States of America, as represented by the Secretary, Department of Health and Human Serv
- Intraluminal stents for treating benign prostatic hyperplasia1 Oct 2026US 2026/0297612 A1Rivermark Medical, Inc.
- Host cell for improving stability of plasmid10 Sep 2026US 2026/0265764 A1Nanjing GenScript Biotech Co., Ltd.
- Generation of neurons by reprogramming of oligodendrocytes and oligodendrocyte precursor cells3 Sep 2026US 2026/0256853 A1The University of North Carolina at Chapel Hill
Most cited
By later US patents
- Interleukin-1α antibodies1,029US 8,034,337 B2Xbiotech, Inc. · 2011
- In vivo production of small interfering RNAS that mediate gene silencing253US 7,691,995 B2University of Massachusetts · 2010
- Isolation of novel AAV'S and uses thereof107US 9,217,155 B2University of Massachusetts · 2015
- Compositions and methods for silencing ebola virus gene expression98US 9,187,748 B22015
- Composition for regulating production of ribonucleic acid89US 11,530,423 B1Wyvern Pharmaceuticals Inc. · 2022